Financial Performance - The company reported a net loss attributable to shareholders of 153.08 million yuan, an increase in loss of 97.08 million yuan year-on-year[5] - Basic earnings per share were -0.40 yuan, compared to -0.16 yuan in the previous year[3] - The company has not yet achieved operating revenue during the reporting period[5] - Other income recognized in 2025 was 18.78 million yuan, a decrease of 79.85 million yuan compared to 2024[8] - The company continues to operate at a loss due to ongoing R&D and operational expenses[7] Assets and Equity - Total assets at the end of the reporting period were 1,716.64 million yuan, a year-on-year increase of 416.32%[8] - Shareholders' equity attributable to the parent company was 1,669.87 million yuan, up 475.38% year-on-year[8] - The company's net asset value per share increased to 3.71 yuan, a rise of 358.02% year-on-year[8] Research and Development - R&D investments remain high, focusing on multiple clinical trials including BEBT-908 and BEBT-701[6] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report as of the announcement date[9]
必贝特(688759) - 2025 Q4 - 年度业绩